{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-26-001485","form_type":"8-K","ticker":"VSBC","cik":"0001697884","company_name":"VITASPRING BIOMEDICAL CO. LTD.","filed_at":"2026-09-10T17:22:10+00:00","discovered_at":"2026-09-10T17:23:01.321756+00:00","generated_at":"2026-09-10T17:23:41.054956+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"VitaSpring Biomedical names Jing-Zhou Chen CEO/CFO, Shao-Hsiang Shih Chairman; Lai resigns","bullets":["Ssu-Chuan Lai resigned as Chairperson, CEO, President, CFO, Secretary, and director effective 11:58 p.m. PT Sept 7, 2026; no disagreement cited.","Jing-Zhou Chen, 40, appointed CEO, President, CFO, and Secretary effective 11:57 p.m. PT Sept 7, 2026; no employment agreement or compensation.","Shao-Hsiang Shih, 54, elected director and appointed Chairman of the Board effective same time; no compensation.","Both new appointees have no family relationships or material interests; indemnification agreements authorized but not yet executed."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-26-001485","json":"https://secwatch.observer/filing/0001640334-26-001485.json","markdown":"https://secwatch.observer/filing/0001640334-26-001485.md","text":"https://secwatch.observer/filing/0001640334-26-001485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1697884/000164033426001485/0001640334-26-001485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1697884/000164033426001485/vsbc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-10T17:23:41.054956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24f00f37d2","claim":"Shao-Hsiang Shih was appointed as Chairman of the Board at VITASPRING BIOMEDICAL CO. LTD..","evidence_excerpt":"Effective at 11:57 p.m. Pacific Time on September 7, 2026, Mr. Shih was appointed Chairman of the Board, to serve at the pleasure of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1697884/000164033426001485/0001640334-26-001485-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"67cac393c1","claim":"Ssu-Chuan Lai resigned as Chief Executive Officer at VITASPRING BIOMEDICAL CO. LTD..","evidence_excerpt":"Effective at 11:58 p.m. Pacific Time on September 7, 2026, immediately following the election of her successor as a director and the appointment of her successor officers as described in Items 5.02(c) and (d) below, Dr. Ssu-Chuan Lai resigned from her positions as Chairperson of the Board, Chief Executive Officer, President, Chief Financial Officer, and Secretary of the Company, and as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1697884/000164033426001485/0001640334-26-001485-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"8021a2d69c","claim":"Jing-Zhou Chen was appointed as Chief Executive Officer at VITASPRING BIOMEDICAL CO. LTD..","evidence_excerpt":"Effective at 11:57 p.m. Pacific Time on September 7, 2026, Dr. Ssu-Chuan Lai, as the sole director then in office, appointed Jing-Zhou Chen as the Company’s Chief Executive Officer, President, Chief Financial Officer, and Secretary, to serve at the pleasure of the Board and until his successor is duly appointed and qualified, or until his earlier death, resignation or removal.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1697884/000164033426001485/0001640334-26-001485-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"efc485f4ae","claim":"Shao-Hsiang Shih was elected as Director at VITASPRING BIOMEDICAL CO. LTD..","evidence_excerpt":"Effective at 11:56 p.m. Pacific Time on September 7, 2026, Ssu-Chuan Lai, as the sole director then in office, elected Shao-Hsiang Shih to serve as a director of the Company, to hold office until the next annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1697884/000164033426001485/0001640334-26-001485-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}